HC Wainwright Reaffirms “Buy” Rating for Kadmon (KDMN)
A number of other research analysts have also weighed in on KDMN. Zacks Investment Research raised shares of Kadmon from a sell rating to a hold rating in a research note on Tuesday, November 21st. WBB Securities lowered shares of Kadmon from a hold rating to a sell rating and set a $3.00 price target on the stock. in a research note on Monday, October 9th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $9.75.
Shares of Kadmon (NYSE:KDMN) opened at $3.57 on Friday. Kadmon has a 12-month low of $2.05 and a 12-month high of $5.93.
A number of institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. purchased a new position in Kadmon in the 2nd quarter worth approximately $114,000. Bank of New York Mellon Corp purchased a new position in Kadmon in the 3rd quarter worth approximately $119,000. Renaissance Technologies LLC purchased a new position in Kadmon in the 1st quarter worth approximately $158,000. Old West Investment Management LLC purchased a new position in Kadmon in the 3rd quarter worth approximately $169,000. Finally, Wells Fargo & Company MN lifted its stake in Kadmon by 17.0% in the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after purchasing an additional 8,742 shares in the last quarter. 51.90% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “HC Wainwright Reaffirms “Buy” Rating for Kadmon (KDMN)” was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/hc-wainwright-reaffirms-buy-rating-for-kadmon-kdmn/1770911.html.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.